Pathogenic autoreactive CD4+ T-cell receptor (CD4+ autoreactive TCR)

The pathogenic autoreactive CD4+ T-cell receptor (TCR) is a heterodimeric surface protein complex that plays a central role in the initiation and progression of autoimmune diseases by recognizing self-peptides presented by Major Histocompatibility Complex class II (MHCII) molecules (Janeway et al., 2001). In conditions such as Type 1 Diabetes and Multiple Sclerosis, these TCRs escape central and peripheral tolerance mechanisms, leading to the activation of CD4+ T-helper cells that orchestrate tissue-specific inflammation (Peakman, 2021). As a therapeutic target, this TCR allows for highly specific intervention; drugs like peptide-MHC-coated nanoparticles (Navacims) are designed to bind these receptors to induce the differentiation of autoreactive cells into regulatory T-cells (Tregs) or trigger T-cell exhaustion (Clemente-Casares et al., 2016). This approach aims to restore immune tolerance without the systemic side effects associated with broad immunosuppressants. Current research focuses on identifying disease-specific peptide-MHCII complexes to develop TCR-mimetic antibodies and soluble pMHC multimers for precision medicine (Santamaria, 2010). Monitoring these targets often involves the use of pMHC tetramers to track the frequency and phenotype of the pathogenic T-cell population in patients.

Other names

Autoreactive T-cell receptorSelf-reactive TCRMHCII-restricted autoreactive TCRPathogenic TCRDisease-specific TCR

Selective binding to the autoreactive TCR to induce T-cell anergy, apoptosis, or phenotypic conversion into regulatory T-cells (Tregs) (Clemente-Casares et al., 2016).